Long-Term Thyroid Outcomes After COVID-19 Vaccination: A Cohort Study of 2 333 496 Patients From the TriNetX Network
The Journal of Clinical Endocrinology & Metabolism · 2025
DOI: 10.1210/clinem/dgaf064 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, 2025. Verfasst von Kai-Lun Cheng und 5 weiteren Autor:innen. Beteiligte Einrichtung: School of Medicine, Chung Shan Medical University, Taichung 40201, Taiwan. Hauptthemen laut MEDLINE: COVID-19 Vaccines, COVID-19, Hypothyroidism, Hyperthyroidism. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 42 Literaturangaben. Gefördert von: Chung Shan Medical University Hospital.
Abstract (Originalsprache)
Context
Reports on long-term thyroid dysfunction following COVID-19 vaccination are limited. Understanding the risk of subacute thyroiditis, hyperthyroidism, and hypothyroidism in vaccinated individuals is crucial for postvaccination monitoring.
Objective
This study evaluated the risk of thyroid dysfunction in individuals vaccinated against COVID-19 compared to unvaccinated individuals, using a large cohort.
Methods
We conducted a retrospective cohort study from January 1, 2022, to December 31, 2023, using the TriNetX database, including 1 166 748 vaccinated and 1 166 748 unvaccinated individuals. Propensity score matching was used to balance baseline characteristics. The primary outcomes were new diagnoses of subacute thyroiditis, hyperthyroidism, and hypothyroidism.
Results
The risk of subacute thyroiditis remained unchanged (95% CIs included 1). A significant reduction in hyperthyroidism risk was observed from 3 to 9 months postvaccination (hazard ratios [HRs]: 0.65-0.89, all 95% CIs below 1), but this trend was not significant at 12 months (HR: 0.99; 95% CI: 0.92-1.06). In contrast, the risk of hypothyroidism significantly increased from 6 to 12 months postvaccination (HR: 1.14-1.30, all 95% CIs above 1). Among mRNA vaccine recipients, the risk of both hyperthyroidism and hypothyroidism was significantly elevated at 12 months (HR: 1.16-2.13).
Conclusion
COVID-19 vaccination was associated with a reduced risk of hyperthyroidism and an increased risk of hypothyroidism, highlighting the need for ongoing thyroid function monitoring.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Medicine, Chung Shan Medical University, Taichung 40201, Taiwan.
- Department of Medical Imaging, Chung Shan Medical University Hospital, Taichung 40201, Taiwan.
- Department of Internal Medicine, Division of Endocrinology and Metabolism, Chung Shan Medical University Hospital, Taichung 40201, Taiwan.
- Department of Medical Research, Chung Shan Medical University Hospital, Taichung 40201, Taiwan.
- Academic Research and Education Support Lead, TriNetX, Cambridge, MA 02140, USA.
- Department of Surgery, Chung Shan Medical University Hospital, Taichung 40201, Taiwan.
ORCID-Profile: Kai-Lun Cheng, Gema Hernández Ibarburu, Hsiang-Lin Lee, James Cheng-Chung Wei
Förderung
- Chung Shan Medical University Hospital
Zitieren
APA
Cheng, K. L., Yu, W. S., Wang, Y. H., Ibarburu, G. H., Lee, H. L., & Wei, J. C. (2025). Long-Term Thyroid Outcomes After COVID-19 Vaccination: A Cohort Study of 2 333 496 Patients From the TriNetX Network. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/clinem/dgaf064
Vancouver
Cheng KL, Yu WS, Wang YH, Ibarburu GH, Lee HL, Wei JC. Long-Term Thyroid Outcomes After COVID-19 Vaccination: A Cohort Study of 2 333 496 Patients From the TriNetX Network. The Journal of Clinical Endocrinology & Metabolism. 2025. doi:10.1210/clinem/dgaf064
BibTeX
@article{Cheng2025,
author = {Cheng, Kai-Lun and Yu, Wei-Shin and Wang, Yu-Hsun and Ibarburu, Gema Hernández and Lee, Hsiang-Lin and Wei, James Cheng-Chung},
title = {Long-Term Thyroid Outcomes After COVID-19 Vaccination: A Cohort Study of 2 333 496 Patients From the TriNetX Network},
journal = {The Journal of Clinical Endocrinology & Metabolism},
year = {2025},
doi = {10.1210/clinem/dgaf064}
}
EUVIMED